Loading patent…
OwnerGuido Galley, Katrin Groebke Zbinden +2inventors
InventorsGuido Galley, Katrin Groebke Zbinden, Roger Norcross, Henri Stalder
Estimating the term…
The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R1, R2, Q, W, X, Y, m, and n are as defined in the specification, and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms. The invention also relates to novel compounds of formula I, compositions containing them, and methods for their preparation.
A method for treating a disorder selected from the group consisting of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders comprising administering to an individual a therapeutically effective amount of a compound of formula I
A compound of formula I
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
The pharmaceutical composition of claim 23, wherein the compound of formula I is selected from the group consisting of
The pharmaceutical composition of claim 25, wherein the compound of formula I is rac-2-(7-tritio-1,2,3,4-tetrahydro-naphthalen-1-yl)-4,5-dihydro-1H-imidazole.
The pharmaceutical composition of claim 27, wherein the compound of formula I is selected from the group consisting of
The pharmaceutical composition of claim 29, wherein the compound of formula I is selected from the group consisting of
The pharmaceutical composition of claim 32, wherein the compound of formula I is (4-(3,4-dihydro-naphthalen-1-yl)-1H-imidazole.
The pharmaceutical composition of claim 34, wherein the compound of formula I is rac-5-chroman-4-yl-1H-imidazole hydrochloride or a tautomer thereof.
The pharmaceutical composition of claim 35, wherein the compound of formula I is selected from the group consisting of
The pharmaceutical composition of claim 37, wherein the compound of formula I is selected from the group consisting of
A pharmaceutical composition comprising about 0.01 mg to about 1000 mg of a compound of formula I
Dependencies are inferred from the claim text.